# Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients

> **NCT04605978** · PHASE2 · COMPLETED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 48 (actual)

## Conditions studied

- Primary Sjögren's Syndrome

## Interventions

- **DRUG:** S95011 concentrate for solution for infusion
- **DRUG:** Placebo concentrate for solution for infusion

## Key facts

- **NCT ID:** NCT04605978
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-03
- **Primary completion:** 2023-01-16
- **Final completion:** 2023-05-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2024-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04605978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04605978, "Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04605978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*